Because SGLT2 inhibitors can lower blood sugar levels, a meta-analysis of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers combined with SGLT2 inhibitors in the treatment of diabetes found that combined therapy increased the risk of hypoglycemia (42). This evidence concerns the gene ACE and Hypoglycemia.